Sara Bortolani,Marco Savarese,Gaetano Vattemi,Silvia Bonanno,Yuri M Falzone,Alessia Pugliese,Guido Primiano,Cristina Sancricca,Diego Lopergolo,Giulia Greco,Chiara Gemelli,Sabrina Ravaglia,Roberta P Bencivenga,Daniele Velardo,Francesca Magri,Maria L Valentino,Marta Cheli,Eleonora Torchia,Matteo Lucchini,Antonio Petrucci,Giulia Ricci,Matteo Garibaldi,Guja Astrea,Anna Rubegni,Corrado I Angelini,Alessandra Ariatti,Filippo M Santorelli,Alessandra Ruggieri,Giovanni Antonini,Gabriele Siciliano,Massimiliano Filosto,Massimiliano Mirabella,Rocco Liguori,Giacomo P Comi,Lucia Ruggiero,Marina Grandis,Roberto Massa,Alessandro Malandrini,Serenella Servidei,Tiziana E Mongini,Carmelo Rodolico,Antonio Toscano,Stefano C Previtali,Paola Tonin,Jordi Diaz-Manera,Mauro Monforte,Enzo Ricci,Lorenzo Maggi,Giorgio Tasca

Abstract:Background and objectives: The diagnostic process for myofibrillar myopathies (MFM) and distal myopathies (DM) is particularly complex because of the large number of causative genes, the existence of still molecularly undefined disease entities, and the overlapping features between the 2 categories. This study aimed to characterize a large cohort of patients affected by MFM and DM and identify the most important diagnostic and prognostic aspects of these diseases. Methods: Patients with either a myopathological diagnosis of MFM or a clinical diagnosis of DM were included in this retrospective multicentric national study. Demographic, genetic, clinical, and histopathologic data of anonymized patients were collected from the neuromuscular centers of the Italian Association of Myology network. Results: Data regarding 132 patients with MFM (mean age 57.0 ± 15.8 years, 49% female) and 298 patients with DM (mean age 50.7 ± 15.9 years, 40% female) were gathered from 20 neuromuscular centers. 69 patients fulfilled the criteria for both groups (distal myopathies with myofibrillar pathology, DM-MP). Molecular confirmation was achieved in 63% of the patients. Fifty-two percent of the patients with MFM carried pathogenic variants in either DES (n = 30), MYOT (n = 20), or DNAJB6 (n = 18), which were also the most frequent disease-causing genes in DM-MP, while GNE (n = 44) and MYH7 (n = 23) were the genes most commonly carrying pathogenic variants in DM. The mean age at onset varied from <25 years in patients with causative variants in MYH7 and DYSF to 59 years in patients with myotilinopathies. Cardiac involvement was reported in 29% of patients with MFM and 16% of patients with DM, with DES and MYH7 variants significantly associated with the development of cardiomyopathy. Respiratory impairment was more prevalent in patients with TTN and DES variants and rare in other disorders such as GNE myopathy and dysferlinopathies, which were instead associated, together with DNAJB6-related and PLIN4-related myopathies, with the risk of losing ambulation during the disease course. Discussion: The Italian cohort of patients with MFM and DM recapitulates the phenotypic heterogeneity and the partial overlap between the 2 groups. However, in relative contrast to the encountered phenotypic variability, only 5 genes accounted for most of the molecular diagnoses. Specific genetic entities are associated with significantly increased risk of developing cardiorespiratory complications or loss of ambulation, which has relevant prognostic implications.

Investigating the prevalence of MFN2 mutations in amyotrophic lateral sclerosis: insights from an Italian cohort

Exploring the Role of CCNF Variants in Italian ALS Patients

Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives

Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study

An Integrative Analysis of Genotype-Phenotype Correlation in Charcot Marie Tooth Type 2A Disease with MFN2 Variants: A Case and Systematic Review

MFN2 mutations in Charcot–Marie–Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics

Clinical, Histopathologic, and Genetic Features of Patients With Myofibrillary and Distal Myopathies: Experience From the Italian Network

Clinical and genetic features of CMT2T in Italian patients confirm the importance of MME pathogenic variants in idiopathic, late-onset axonal neuropathies

Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot–Marie–Tooth type 2A

A cellular assay to determine the fusion capacity of MFN2 variants linked to Charcot-Marie-Tooth type 2A

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A

Genotype-phenotype correlation in seven motor neuron disease families with novel ALS2 mutations

A Cohort Study of Han Chinese MFN2-related Charcot–Marie–Tooth 2A

The Genotype and Phenotype Features in a Large Chinese MFN2 Mutation Cohort

Exome Sequencing Reveals a Novel MFN2 Missense Mutation in a Chinese Family with Charcot-Marie-Tooth Type 2A

Mitochondrial genome variants associated with Amyotrophic Lateral Sclerosis and their haplogroup distribution

A novel variant in MFN2 linked to a lethal disorder of neonatal onset

Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A

Phenotype Analysis of Fused in Sarcoma Mutations in Amyotrophic Lateral Sclerosis

MFN2-related genetic and clinical features in a cohort of Chinese CMT2 patients

One Multilocus Genomic Variation Is Responsible for a Severe Charcot-Marie-Tooth Axonal Form